Unal M, Peyman G A, Liang C, Hegazy H, Molinari L C, Chen J, Brun S, Tarcha P J
LSU Eye Center, Louisiana State University Medical Center School of Medicine, New Orleans 70112-2234, USA.
Retina. 1999;19(5):442-6. doi: 10.1097/00006982-199909000-00013.
To investigate the ocular toxicity and clearance of intravitreal clarithromycin lactobionate (Klaricid) and to determine the highest nontoxic dose.
To evaluate toxicity, 24 New Zealand white rabbits were divided into six groups (four rabbits each). Rabbits were examined preoperatively and electroretinography (ERG) was performed. The left eyes of the animals served as controls and received intravitreal injection of 0.1 mL sterile water. Klaricid (0.1 mL) was injected into the midvitreous cavity of the right eyes at concentrations of 25 microg, 250 microg, 500 microg, 1.0 mg, 2.0 mg, and 4.0 mg/0.1 mL. The animals were followed up to 15 days postinjection by clinical examination and ERG. The animals were killed and the eyes were enucleated and processed for light microscopy. Ten New Zealand rabbits were used for the vitreous clearance study as drug test rabbits and two additional rabbits were used to generate control retina and vitreous. The highest nontoxic dose (1 mg) was injected into the vitreous and the concentration of clarithromycin in the vitreous was determined using high-performance liquid chromatography at various time intervals after injection.
Cataract occurred after intravitreal doses of 2.0 and 4.0 mg. Electroretinography showed decreasing b-wave amplitude with both dark- and light-adapted stimulus in the 4.0-mg group; it was normal in other groups. Histopathologic sections showed localized retinal necrosis and disorganization with the 2.0 and 4.0 mg dosage. No histologic changes were found in the other groups. The half-life of intravitreal clarithromycin was found to be 2 hours. No metabolites of clarithromycin were observed in the vitreous samples.
Intravitreal clarithromycin lactobionate is nontoxic to rabbit eyes up to a dose of 1.0 mg. Because of its broad-spectrum antibiotic effect and appropriate half-life in the vitreous, it may be a good choice for intravitreal treatment of susceptible organisms.
研究玻璃体内注射乳糖酸克拉霉素(克拉仙)的眼毒性和清除情况,并确定最高无毒剂量。
为评估毒性,将24只新西兰白兔分为六组(每组4只)。术前对兔子进行检查并进行视网膜电图(ERG)检测。动物的左眼作为对照,玻璃体内注射0.1 mL无菌水。将克拉仙(0.1 mL)以25微克、250微克、500微克、1.0毫克、2.0毫克和4.0毫克/0.1 mL的浓度注入右眼的玻璃体腔中部。通过临床检查和ERG对动物进行注射后长达15天的随访。处死动物,摘除眼球并进行光镜检查。选用10只新西兰兔作为药物试验兔进行玻璃体清除研究,另外选用2只兔来获取对照视网膜和玻璃体。将最高无毒剂量(1毫克)注入玻璃体,并在注射后的不同时间间隔使用高效液相色谱法测定玻璃体内克拉霉素的浓度。
玻璃体内注射2.0毫克和4.0毫克剂量后出现白内障。视网膜电图显示,在4.0毫克组中,暗适应和明适应刺激下b波振幅均降低;其他组均正常。组织病理学切片显示,2.0毫克和4.0毫克剂量组出现局部视网膜坏死和结构紊乱。其他组未发现组织学变化。发现玻璃体内克拉霉素的半衰期为2小时。在玻璃体样本中未观察到克拉霉素的代谢产物。
玻璃体内注射乳糖酸克拉霉素剂量达1.0毫克时对兔眼无毒。由于其具有广谱抗菌作用且在玻璃体内半衰期适宜,它可能是玻璃体内治疗易感病原体的良好选择。